At Kite, a Gilead Company, our singular focus is achieving cures with cell therapy. Our goal is to bring the promise of cell therapy to as many eligible patients as possible who may benefit. Since 2009, Kite has been at the forefront of cancer immunotherapy. Today, we are proud to be the leader in engineered T cell therapy for hematologic malignancies, but we recognize that this is just the beginning. Patients are at the heart of our focus on the cure, which is why we are committed to pursuing cell therapy as a transformative treatment option for as many patients as possible who may benefit. Unlike traditional pharmaceutical manufacturing, our therapies are not created on an assembly line. Cell therapy specialists at our manufacturing facilities reengineer a patient’s own immune cells to attack and fight their cancer cells — one patient at a time. That sense of connection to the people we serve motivates us daily at Kite. Our corporate headquarters are located in Santa Monica, California, and we have dedicated cell therapy manufacturing facilities in California, Maryland and the Netherlands. If you’re passionate about bringing the curative potential of cell therapy to more eligible patients, let’s talk. See our community guidelines: http://bit.ly/2DznMNw
External link for Kite Pharma
Kite Pharma reposted this
Manufacturing is where CAR T becomes real. Every therapy is made-to-order. Every step in the process has to be done right, the first time. And every single day matters. Our promise is fast and reliable CAR T manufacturing for patients no matter where they are. Because we know patients don't have time to wait. Watch to learn how CAR T-cell therapy helps deliver hope to patients. https://gilead.inc/4uPBZgM
Thirty-two Kite volunteers joined our local partner, Frederick County Public Schools, at their FCPS Science Fair, to spark curiosity and inspire the next generation of scientists and innovators near our cell therapy manufacturing facility in Frederick, Maryland. Through hands-on activities on safe sample collection, a coloring book that brought the CAR T manufacturing process to life and an awards ceremony that recognized standout middle and high school projects, our teams helped connect classroom curiosity to real-world science.
CAR T may feel heavy both physically and mentally, but you don’t have to carry that weight on your own. Learn more at CARTandMeInfo.com.
Behind every CAR T journey is a caregiver helping make treatment possible. For Angela, that meant learning as much as she could because with CAR T-cell therapy, a 24/7 caregiver is required for at least two weeks after infusion. We're working with American Cancer Society to ensure families and care partners have the resources they need to fill this role through education and support services. Learn more at cancer.org/CARTCaregivers.
Every story in our Gilead and Kite Identity + Innovation series adds a new layer to how we understand our impact. This AANHPI Heritage Month, we’re highlighting Raaed Syed, whose perspective is shaped by perseverance and a deep sense of community. Influenced by his experiences across cultures, Raaed brings a thoughtful approach to problem solving—one that focuses on identifying gaps and unlocking opportunity. His connection to family, community and Gilead’s Asian employee resource group continues to inspire his commitment to fostering inclusion and driving meaningful impact.
This #EarthMonth, we’re proud to share a milestone that reflects our ongoing commitment to sustainability: our Kite Santa Monica Research, Development and Manufacturing Center has achieved LEED Gold® certification for Operations and Maintenance. This recognition represents years of dedicated effort from our Facilities & Engineering teams, partners and site leaders to enhance energy efficiency, reduce environmental impact and maintain smarter, more sustainable operations, all while supporting critical science and manufacturing. Earning LEED Gold® underscores our focus on responsible resource use, continuous improvement and ensuring safe, efficient and resilient environments for our teams.
Kite Pharma reposted this
#GileadNews: Today, we completed our acquisition of Arcellx, which strengthens our oncology portfolio and the long-term potential of an investigational cell therapy for multiple myeloma. By consolidating ownership of anito-cel, we’re better positioned to accelerate development and maximize potential to bring innovation to patients who need it most. Read more: https://gilead.inc/48rJHVO
From our manufacturing facilities in the United States to our site in the Netherlands, our cell therapy specialists are committed to bringing CAR T to appropriate patients around the world. Hear from Tiffany Pinkowski, Kolton Peck and Esmée Collenteur as they share what this important work means to them.
Every breakthrough is powered by the people who turn possibility into progress, including cell therapy specialists like Kevin Liang. Kevin is motivated by the opportunity to advance the next generation of innovation while helping broaden treatment options for appropriate patients. His dedication embodies our shared commitment to pushing science forward and delivering meaningful new possibilities in care.